ArriVent Biopharma claims best-in-class potential in gastrointestinal cancers for its new asset, but it’s not specifying the class. It’s possible the Phase 1-ready drug goes after claudin 18.2, a hot target for GI cancer drug research that recently welcomed its first FDA-approved therapy and is in pursuit by several companies.
The post Cancer Biotech ArriVent Lands an ADC for GI Malignancies and Makes Best-in-Class Claim appeared first on MedCity News.
